Gane, E. J., Pianko, S., Roberts, S. K., Thompson, A. J., Zeuzem, S., Zuckerman, E., Ben-Ari, Z., Foster, G. R., Agarwal, K.
, Laursen, A. L., Gerstoft, J., Gao, W., Huang, H.-C., Fitzgerald, B., Fernsler, D., Li, J. J., Grandhi, A., Liu, H., Su, F.-H. ... Esteban, R. (2017).
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
The Lancet Gastroenterology and Hepatology,
2(11), 805-813.
https://doi.org/10.1016/S2468-1253(17)30159-0